** Shares of Hansoh Pharmaceutical Group 3692.HK rise 3.8% to HK$27.5, their highest levels since August 2021
** Stock marks biggest intraday pct gain since May 20, and on track for a third straight session of rise, if current trend holds
** Stock is fifth-biggest pct gainer on the Hang Seng Commerce & Industry Index .HSNC, which climbs 0.8%
** Hansoh says its innovative drug Aumolertinib Mesilate Tablets for lung cancer has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for marketing
** The Hang Seng Biotech Index .HSHKBIO rises 3.1% and the Hang Seng Index .HSI adds 0.5%
** YTD, stock up 56.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.